Pitavastatin is a novel Mcl-1 inhibitor that overcomes paclitaxel resistance in triple-negative breast cancer
PITA's inhibition of Mcl-1 represents a novel mechanism to address treatment-refractory metastatic TNBC. Further assessment of PITA's therapeutic potential is warranted.
Authors
- Soeun Park (ORCID: https://orcid.org/0000-0001-6421-2107)
- Yoon Jae Kim (ORCID: https://orcid.org/0000-0001-8477-6823)
- Lee Farrand (ORCID: https://orcid.org/0000-0001-9785-3429)
- Juyeon Seo (ORCID: https://orcid.org/0000-0002-4521-8084)
- Yong Koo Kang
- Dongmi Ko
- Jung Min Park (ORCID: https://orcid.org/0000-0002-8817-2856)
- Ji Young Kim (ORCID: https://orcid.org/0000-0002-1675-8604)
- Seongjae Kim (ORCID: https://orcid.org/0000-0002-9592-6556)
- Min-Su Park (ORCID: https://orcid.org/0000-0002-0707-2969)
- Jae Hong Seo
- Eunsun Jung (ORCID: https://orcid.org/0000-0002-5900-6138)
- Kee Dal Nam
Institutions
- Korea University Medical Center (KR)
- Korea University (JP)
- The University of Adelaide (AU)
Publication Details
- Journal
- Experimental Hematology and Oncology
- Published
- 2025-10-22
- DOI
- https://doi.org/10.1186/s40164-025-00716-6
- Primary Topic
- Cancer, Lipids, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Research Foundation
- Korea Health Industry Development Institute
- Ministry of Science and ICT, South Korea